Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Volume 59, Number 4, August 27, 2002
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shimazaki, H.
Right arrow Articles by Nishizawa, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shimazaki, H.
Right arrow Articles by Nishizawa, M.
Related Collections
Right arrow Gait disorders/ataxia
Right arrow Ocular motility

Neurology 2002;59:590-595
© 2002 American Academy of Neurology

Early-onset ataxia with ocular motor apraxia and hypoalbuminemia

The aprataxin gene mutations

H. Shimazaki, MD, Y. Takiyama, MD PhD, K. Sakoe, PhD, K. Ikeguchi, MD PhD, K. Niijima, MD PhD, J. Kaneko, MD PhD, M. Namekawa, MD, T. Ogawa, MD, H. Date, PhD, S. Tsuji, MD PhD, I. Nakano, MD PhD and M. Nishizawa, MD PhD

From the Department of Neurology (Drs. Shimazaki, Takiyama, Sakoe, Ikeguchi, Namekawa, Ogawa, and Nakano), Jichi Medical School, Tochigi; Niijima Clinic (Dr. Niijima), Tochigi; Kaneko Clinic (Dr. Kaneko), Gunma; Department of Neurology (Drs. Date and Tsuji), Brain Research Institute, Niigata University; and Center for Neurological Diseases (Dr. Nishizawa), International University of Health and Welfare, Tochigi, Japan.

Address correspondence and reprint requests to Dr. Takiyama, Department of Neurology, Jichi Medical School, Tochigi 329-0498, Japan; e-mail: ytakiya{at}ms.jichi.ac.jp

Background: Early-onset ataxia with hypoalbuminemia is regarded as a variant form of Friedreich ataxia in Japan. Early-onset ataxia with hypoalbuminemia and ataxia with ocular motor apraxia have been considered as the same clinical entity because of the recent identification of a common mutation in the aprataxin gene. A new clinical entity named early-onset ataxia with ocular motor apraxia and hypoalbuminemia (EAOH) has been proposed to explain these two diseases.

Objective: To disclose the clinical features of EAOH and to identify the mutations in the aprataxin gene in six patients in four Japanese families with EAOH.

Methods: The clinical features, laboratory findings, sural nerve biopsy results, and brain MRI or CT findings for these patients were evaluated, and molecular analysis was performed, which involved sequencing of the aprataxin gene directly or use of the subcloning method.

Results: Cerebellar ataxia and peripheral neuropathy were noted in all six patients. Ocular motor apraxia was observed in five patients; two of these patients had obvious head thrust. Choreiform movements of the limbs and mental deterioration were observed in five patients. Although foot deformity was noted in five patients, kyphoscoliosis was noted only in one patient. In all patients, hypoalbuminemia and hypercholesterolemia were evident, and brain MRI or CT showed marked cerebellar atrophy. Nerve biopsy revealed depletion of large myelinated fibers in three of the five patients examined. Molecular analysis of the aprataxin gene revealed an insertion mutation (insT at nt167) and two missense mutations (A-to-G transition at nt80 and C-to-T transition at nt95, the former being novel).

Conclusion: We found clinical heterogeneity in the patients with EAOH in this study. With the disease course, the choreiform movements tended to reduce in degree, and hypoalbuminemia became evident. Molecular analysis identified one insertion and two missense mutations including a novel missense one, which was located at a highly conserved amino acid residue in the aprataxin gene product.




This article has been cited by other articles:


Home page
BMJ Case ReportsHome page
G. Yoon, R. Westmacott, L. MacMillan, N. Quercia, P. Koutsou, A. Georghiou, K. Christodoulou, and B. Banwell
Complete deletion of the aprataxin gene: ataxia with oculomotor apraxia type 1 with severe phenotype and cognitive deficit
BMJ Case Reports, February 2, 2009; 2009(jan27_1): bcr0820080688 - bcr0820080688.
[Abstract] [Full Text]


Home page
J. Neurol. Neurosurg. PsychiatryHome page
G Yoon, R Westmacott, L MacMillan, N Quercia, P Koutsou, A Georghiou, K Christodoulou, and B Banwell
Complete deletion of the aprataxin gene: ataxia with oculomotor apraxia type 1 with severe phenotype and cognitive deficit
J. Neurol. Neurosurg. Psychiatry, February 1, 2008; 79(2): 234 - 236.
[Full Text] [PDF]


Home page
J. Biol. Chem.Home page
H. F. Seidle, P. Bieganowski, and C. Brenner
Disease-associated Mutations Inactivate AMP-Lysine Hydrolase Activity of Aprataxin
J. Biol. Chem., June 3, 2005; 280(22): 20927 - 20931.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Criscuolo, P. Mancini, F. Sacca, G. De Michele, A. Monticelli, L. Santoro, V. Scarano, S. Banfi, and A. Filla
Ataxia with oculomotor apraxia type 1 in Southern Italy: Late onset and variable phenotype
Neurology, December 14, 2004; 63(11): 2173 - 2175.
[Abstract] [Full Text] [PDF]


Home page
Mol. Cell. Biol.Home page
H. Luo, D. W. Chan, T. Yang, M. Rodriguez, B. P.-C. Chen, M. Leng, J.-J. Mu, D. Chen, Z. Songyang, Y. Wang, et al.
A New XRCC1-Containing Complex and Its Role in Cellular Survival of Methyl Methanesulfonate Treatment
Mol. Cell. Biol., October 1, 2004; 24(19): 8356 - 8365.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
R. Amouri, M. -C. Moreira, M. Zouari, G. El Euch, C. Barhoumi, M. Kefi, S. Belal, M. Koenig, and F. Hentati
Aprataxin gene mutations in Tunisian families
Neurology, September 14, 2004; 63(5): 928 - 929.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
N. Gueven, O. J. Becherel, A. W. Kijas, P. Chen, O. Howe, J. H. Rudolph, R. Gatti, H. Date, O. Onodera, G. Taucher-Scholz, et al.
Aprataxin, a novel protein that protects against genotoxic stress
Hum. Mol. Genet., May 15, 2004; 13(10): 1081 - 1093.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
I. Le Ber, N. Bouslam, S. Rivaud-Pechoux, J. Guimaraes, A. Benomar, C. Chamayou, C. Goizet, M.-C. Moreira, S. Klur, M. Yahyaoui, et al.
Frequency and phenotypic spectrum of ataxia with oculomotor apraxia 2: a clinical and genetic study in 18 patients
Brain, April 1, 2004; 127(4): 759 - 767.
[Abstract] [Full Text] [PDF]


Home page
BrainHome page
I. Le Ber, M.-C. Moreira, S. Rivaud-Pechoux, C. Chamayou, F. Ochsner, T. Kuntzer, M. Tardieu, G. Said, M.-O. Habert, G. Demarquay, et al.
Cerebellar ataxia with oculomotor apraxia type 1: clinical and genetic studies
Brain, December 1, 2003; 126(12): 2761 - 2772.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
C. Tranchant, M. Fleury, M. C. Moreira, M. Koenig, and J. M. Warter
Phenotypic variability of aprataxin gene mutations
Neurology, March 11, 2003; 60(5): 868 - 870.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2002 by AAN Enterprises, Inc.